IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, is pleased to announce the agenda topics for its upcoming Investor R&D Day. This highly anticipated webcast event, hosted by IDEAYA, will take place on Monday, December 4, 2023, from 8:00 am to 9:30 am ET.
During this event, IDEAYA’s esteemed management team and key opinion leaders will deliver presentations that offer valuable scientific insights and highlight exciting clinical development opportunities across IDEAYA’s synthetic lethality pipeline. Specifically, the focus will be on IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, GSK101/IDE705 (Pol Theta Helicase) in Phase 1, and the Werner Helicase program, which is scheduled for IND submission in 2024. These presentations will provide a comprehensive overview of the progress and potential of these groundbreaking programs.
Furthermore, IDEAYA will showcase its next-generation initiatives for MTAP-deletion, including a wholly-owned program that aims to nominate a development candidate in 2024. Additionally, IDEAYA will present multiple first-in-class clinical combination opportunities, further demonstrating its commitment to innovation and advancing the field of precision medicine.
The IDEAYA Investor R&D Day Webcast agenda is as follows:
– Welcome and Introduction
– Overview of IDEAYA’s Precision Medicine Oncology Platform
– Scientific Insights and Clinical Development Opportunities for IDE397 (MAT2A)
– Advancements and Potential of IDE161 (PARG)
– Progress Update on GSK101/IDE705 (Pol Theta Helicase)
– Werner Helicase Program: IND Submission Plans for 2024
– Next Generation Initiatives for MTAP-Deletion
– First-in-Class Clinical Combination Opportunities
We invite investors, analysts, and all stakeholders to join us for this event.